Skip to main content
Signal8

Syros Pharmaceuticals, Inc. (SYRS)

Sector: Biotechnology

Industry: Biotechnology

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

OTC:SYRSHealthcare
$0.0001
CLOSED
Mkt Cap$3K
EV-
Float26.83M
O/S26.83M
VOL2K sh
$ Vol$0
RVOL0.35×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
Syros Pharmaceuticals, Inc. logoOTC:SYRSClosed$0.0001
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20260.00010.00010.00010.00012,244
Nov 13, 20260.00010.00010.00010.00012,299
Nov 12, 20260.00010.00010.00010.000110,994
Nov 11, 20260.00040.00040.00040.00043,142
Nov 10, 20260.00040.00040.00040.0004516
Nov 9, 20260.00040.00040.00040.00043,092
Nov 6, 20260.00040.00040.00040.000427,171
Nov 5, 20260.00040.00040.00040.00047,527
Nov 4, 20260.00040.00040.00040.00041,055
Nov 3, 20260.00040.00040.00040.0004999
Nov 2, 20260.00040.00040.00040.00048,588
Oct 30, 20260.00040.00040.00040.00041,947
Oct 29, 20260.00040.00040.00040.00045,825
Oct 28, 20260.00040.00040.00040.000411,447
Oct 27, 20260.00040.00040.00040.00044,782
Oct 26, 20260.00040.00040.00040.00041,498
Oct 22, 20260.00040.00040.00040.0004202
Oct 21, 20260.00040.00040.00040.0004803
Oct 20, 20260.00040.00040.00040.000430,546
Oct 19, 20260.00040.00040.00040.00043,024
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
4
HOLD
5
SELL
0
TOTAL9
Insider Trades
InsiderTypeShares
Simonian Nancy A profile photoSimonian Nancy ASale37.1K
Simonian Nancy A profile photoSimonian Nancy ASale134.7K
Quirk Gerald E profile photoQuirk Gerald ESale46.7K
Stephens Kristin profile photoStephens KristinSale36.1K
Chee Conley profile photoChee ConleySale134.8K
Haas Jason profile photoHaas JasonSale137.8K
Shareholders
--
Institutional
(0)
--
Insiderⓘ
(3)
--
5%+ Owners
(4)
--
Unattributed (incl. retail)ⓘ
Top Shareholders
NameShares%
Bain Capital Life Sciences Fund II, L.P. 2 logo
Bain Capital Life Sciences Fund II, L.P. 2
· may incl. warrants· stale · filed Nov 2024
2.8M10.0%
Avidity Partners Management LP logo
Avidity Partners Management LP
· filed Feb 2025
2.0M7.6%
Invus Public Equities, L.P. logo
Invus Public Equities, L.P.
· filed Feb 2025
0+1.1M via warrants3.8%
Samsara BioCapital, L.P. logo
Samsara BioCapital, L.P.
· filed Mar 2025
0+707.1K via warrants2.6%
Ally Bridge MedAlpha Master Fund L.P. logo
Ally Bridge MedAlpha Master Fund L.P.
· may incl. warrants· stale · filed Feb 2024
571.0K2.6%
Adage Capital Management, L.P. logo
Adage Capital Management, L.P.
· filed Feb 2025
531.9K2.0%
Blue Owl Capital Holdings LP logo
Blue Owl Capital Holdings LP
· filed Nov 2024
515.9K1.9%
Young Richard A profile photo
Young Richard A
Director
10.7K--
AKKARAJU SRINIVAS profile photo
AKKARAJU SRINIVAS
Director
9.3K--
Simonian Nancy A profile photo
Simonian Nancy A
Director
4.0K--
Sources: Form 4, 13D/13G
Insiders & Institutional Holders

Insiders

About

Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression.

Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012.

Its corporate headquarters are located in Cambridge, Massachusetts.

Key Metrics
Market Cap$2,683
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateJun 30, 2016
Shares Outstanding26.83M
Authorized Shares
Float26.83M
52-Week Range
$0.0000$0.0200
$0.0001(0th percentile)
Volume
Average Daily Volume6.38K
2.24K today vs 6.38K avg(-65%)

30d Avg

6.38K

60d Avg

13.27K

90d Avg

13.82K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Syros Pharmaceuticals, Inc. (OTC: SYRS) traded at $0.0001 on Nov 16, 2026. 52-week range: $0.0000 to $0.0200. The company is in the Healthcare sector (Biotechnology).